Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.67 |
| ▸ | DRD2 | P14416 | 4/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.54 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.54 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.54 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15453217 | 0.90 | HTR1A (0.63) | HTR1ADRD2ABCB1MGLLPTGER1 | |
| SCHEMBL8506779 | 0.88 | HTR1A (0.51) | HTR1ADRD2ABCB1MGLLPTGER1 | |
| SCHEMBL18002776 | 0.84 | PTPN1 (0.51) | HTR1ADRD2ABCB1MGLLPTGER1 | |
| SCHEMBL27344145 | 0.83 | HTR1A (0.67) | HTR1ADRD2ABCB1MGLLPTGER1 | |
| SCHEMBL872421 | 0.83 | HTR1A (0.61) | HTR1ADRD2ABCB1MGLLPTGER1 | |
| SCHEMBL5547648 | 0.81 | HTR1A (0.63) | HTR1ADRD2ABCB1MGLLPTGER1 | |
| SCHEMBL17197391 | 0.80 | HTR1A (0.79) | HTR1ADRD2ABCB1MGLLPTGER1 | |
| SCHEMBL4183309 | 0.80 | HTR1A (1.00) | HTR1ADRD2ABCB1PTGER1PTGER4 | |
| SCHEMBL9695947 | 0.79 | CCNB2 (0.58) | HTR1ADRD2PTGER1PTGER4PTGER3 | |
| SCHEMBL910556 | 0.79 | L3MBTL1 (0.56) | GAAMAPTMAPK1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140039171-A1 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-06 | — | — | US | disclosed |
| EP-2682399-A1 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS | Meiji Seika Pharma Co., Ltd. (JP) | 2014-01-08 | — | — | EP | disclosed |
| CN-103391944-A | Novel macrolide intermediate and novel production process | MEIJI SEIKA PHARMA CO LTD | 2013-11-13 | — | — | CN | disclosed |
| US-20050209446-A1 | Novel 15-membered cyclic azalide, novel 16-membered cyclic diazalide derivative, and process for producing these | MEIJI SEIKA KAISHA LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| CN-1639181-A | Novel 15-membered cyclic azalide, novel 16-membered cyclic diazalide derivative, and process for producing these | MEIJI SEIKA KAISHA (JP) | 2005-07-13 | — | — | CN | disclosed |
| EP-1479687-A1 | NOVEL 15-MEMBERED CYCLIC AZALIDE, NOVEL 16-MEMBERED CYCLIC DIAZALIDE DERIVATIVE, AND PROCESS FOR PRODUCING THESE | MEIJI SEIKA KAISHA LTD. (JP) | 2004-11-24 | — | — | EP | disclosed |
| EP-0844000-A1 | Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis | SANKYO COMPANY LIMITED (JP) | 1998-05-27 | — | — | EP | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039171-A1 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS | MRPL21, PIGS, CYP51A1 | HTR1A 2224/4885DRD2 2428/4885ABCB1 978/4885 |
| US-20050209446-A1 | Novel 15-membered cyclic azalide, novel 16-membered cyclic diazalide derivative, and process for producing these | PRMT9, DHRS9, MRPL9 | HTR1A 4086/4885DRD2 37/4885ABCB1 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.